Renaissance Technologies (RenTech)'s CRVS Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 81,310 shares of Corvus Pharmaceuticals, Inc. (CRVS) worth $1.19 M, representing 0.00% of the portfolio. First purchased in 2017-Q1, this long-term strategic position has been held for 36 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in CRVS, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2021, adding 429,362 shares. Largest reduction occurred in Q4 2022, reducing 326,887 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Corvus Pharmaceuticals (CRVS) Holding Value Over Time
Track share changes against reported price movement
Quarterly Corvus Pharmaceuticals (CRVS) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +81,310 | New Buy | 81,310 | $14.63 |
| Q3 2025 | -165,188 | Sold Out | 0 | $0.00 |
| Q2 2025 | -99,800 | Reduce 37.66% | 165,188 | $4.00 |
| Q1 2025 | -125,700 | Reduce 32.17% | 264,988 | $3.18 |
| Q4 2024 | +4,100 | Add 1.06% | 390,688 | $5.35 |
| Q3 2024 | -177,344 | Reduce 31.45% | 386,588 | $5.28 |
| Q2 2024 | -73,100 | Reduce 11.48% | 563,932 | $1.82 |
| Q1 2024 | +49,600 | Add 8.44% | 637,032 | $1.78 |
| Q4 2023 | +165,689 | Add 39.29% | 587,432 | $1.76 |
| Q3 2023 | -67,930 | Reduce 13.87% | 421,743 | $1.46 |
| Q2 2023 | -16,359 | Reduce 3.23% | 489,673 | $0.00 |
| Q1 2023 | -142,600 | Reduce 21.98% | 506,032 | $0.00 |
| Q4 2022 | -326,887 | Reduce 33.51% | 648,632 | $0.00 |
| Q3 2022 | +12,587 | Add 1.31% | 975,519 | $0.82 |
| Q2 2022 | +61,800 | Add 6.86% | 962,932 | $0.99 |
| Q1 2022 | -142,600 | Reduce 13.66% | 901,132 | $1.64 |
| Q4 2021 | +429,362 | Add 69.89% | 1.04 M | $2.41 |
| Q3 2021 | -43,700 | Reduce 6.64% | 614,370 | $4.84 |
| Q2 2021 | -5,400 | Reduce 0.81% | 658,070 | $2.67 |
| Q1 2021 | -133,600 | Reduce 16.76% | 663,470 | $3.08 |
| Q4 2020 | -77,930 | Reduce 8.91% | 797,070 | $3.56 |
| Q3 2020 | -156,900 | Reduce 15.20% | 875,000 | $4.01 |
| Q2 2020 | +101,200 | Add 10.87% | 1.03 M | $2.72 |
| Q1 2020 | +24,500 | Add 2.70% | 930,700 | $2.11 |
| Q4 2019 | +54,422 | Add 6.39% | 906,200 | $5.44 |
| Q3 2019 | +18,680 | Add 2.24% | 851,778 | $3.01 |
| Q2 2019 | +51,398 | Add 6.58% | 833,098 | $3.74 |
| Q1 2019 | +119,400 | Add 18.03% | 781,700 | $4.02 |
| Q4 2018 | +265,400 | Add 66.87% | 662,300 | $3.67 |
| Q3 2018 | +72,000 | Add 22.16% | 396,900 | $8.58 |
| Q2 2018 | -101,800 | Reduce 23.86% | 324,900 | $10.98 |
| Q1 2018 | +192,500 | Add 82.19% | 426,700 | $11.53 |
| Q4 2017 | +39,900 | Add 20.54% | 234,200 | $10.36 |
| Q3 2017 | +57,200 | Add 41.72% | 194,300 | $15.94 |
| Q2 2017 | +79,300 | Add 137.20% | 137,100 | $12.10 |
| Q1 2017 | +57,800 | New Buy | 57,800 | $20.78 |
Renaissance Technologies (RenTech)'s Corvus Pharmaceuticals Investment FAQs
Renaissance Technologies (RenTech) first purchased Corvus Pharmaceuticals, Inc. (CRVS) in Q1 2017, acquiring 57,800 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Corvus Pharmaceuticals, Inc. (CRVS) for 36 quarters since Q1 2017.
Renaissance Technologies (RenTech)'s largest addition to Corvus Pharmaceuticals, Inc. (CRVS) was in Q4 2021, adding 1,043,732 shares worth $2.52 M.
According to the latest 13F filing for Q1 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 81,310 shares of Corvus Pharmaceuticals, Inc. (CRVS), valued at approximately $1.19 M.
As of the Q1 2026 filing, Corvus Pharmaceuticals, Inc. (CRVS) represents approximately 0.00% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Corvus Pharmaceuticals, Inc. (CRVS) was 1,043,732 shares, as reported at the end of Q4 2021.